ProPhase Labs, Inc.
PRPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.02 | -0.03 |
| FCF Yield | -127.69% | -37.29% | 32.25% | -32.77% |
| EV / EBITDA | -1.19 | -3.96 | 2.58 | 5.35 |
| Quality | ||||
| ROIC | -120.09% | -21.40% | 26.46% | 15.43% |
| Gross Margin | -2.22% | 36.59% | 57.61% | 41.51% |
| Cash Conversion Ratio | 0.35 | 0.68 | 1.55 | -2.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -61.92% | -17.50% | 103.68% | 100.03% |
| Free Cash Flow Growth | -27.17% | -158.88% | 237.99% | -316.96% |
| Safety | ||||
| Net Debt / EBITDA | -0.74 | -1.33 | -0.07 | 0.57 |
| Interest Coverage | -11.53 | -16.95 | 30.88 | 8.54 |
| Efficiency | ||||
| Inventory Turnover | 6.05 | 7.33 | 13.08 | 10.05 |
| Cash Conversion Cycle | 418.19 | 226.75 | 96.73 | 154.97 |